| Identification | Back Directory | [Name]
BMT-090605 | [CAS]
1551403-51-0 | [Synonyms]
BMT-090605
BMT090605,BMT 090605
Benzo[c][2,7]naphthyridine-9-carbonitrile, 8-[[(2S)-2-amino-4-methylpentyl]oxy]-5,6-dihydro-4,6-dimethyl-5-oxo- | [Molecular Formula]
C21H24N4O2 | [MDL Number]
MFCD34469133 | [MOL File]
1551403-51-0.mol | [Molecular Weight]
364.44 |
| Chemical Properties | Back Directory | [Boiling point ]
614.4±55.0 °C(Predicted) | [density ]
1.24±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
9.49±0.42(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
BMT-090605 is a potent, selective the adapter protein-2 associated kinase 1 (AAK1) inhibitor with an IC50 value of 0.6 nM. BMT-090605 shows antinociceptive activity. BMT-090605 inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50 values of 45 nM and 60 nM, respectively. BMT-090605 can be used for the research of neuropathic pain[1]. | [in vivo]
BMT-090605 (intrathecal; 0.3-3 μg/rat) causes antinociception by inhibiting AAK1 in the spinal cord[1]. | Animal Model: | Male Sprague-Dawley rats (chronic constriction injury (CCI) model)[1] | | Dosage: | 0.3-3 μg/rat | | Administration: | Intrathecal | | Result: | Caused a dose-dependent reduction in thermal hyperalgesia.
|
| [References]
[1] Kostich W, et al. Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain. J Pharmacol Exp Ther. 2016 Sep;358(3):371-86. DOI:10.1124/jpet.116.235333 |
|
|